341291
Kp7-6
≥98% (HPLC), lyophilized powder, Fas/FasL antagonist, Calbiochem®
Synonym(s):
Fas/FasL Antagonist, Kp7-6, H-YC*DEHFC*Y-OH, Cyclic [Cys-Cys disulfide], Kp7-6
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C48H56N10O15S2
Molecular Weight:
1077.15
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
lyophilized powder
Quality level:
Storage condition:
OK to freeze, desiccated (hygroscopic), protect from light
Product Name
Fas/FasL Antagonist, Kp7-6, The Fas/FasL Antagonist, Kp7-6 controls the biological activity of Fas/FasL. This small molecule/inhibitor is primarily used for Cancer applications.
Quality Level
assay
≥98% (HPLC)
form
lyophilized powder
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic), protect from light
color
white
solubility
DMSO: 5 mg/mL
shipped in
ambient
storage temp.
2-8°C
General description
An exocyclic cysteine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (Kd = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR.
An exocyclic cystine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (Kd = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling pathways. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR.
Biochem/physiol Actions
Cell permeable: no
Kd = 11.2 & 13.2 µM for FasL and Fas (CD95/APO-1), respectively
Primary Target
Fas/FasL-mediated cellular apoptotic signals
Fas/FasL-mediated cellular apoptotic signals
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Physical form
Supplied as a trifluoroacetate salt.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Carmona, E.M., et al. 2006. J. Immunol.177, 459.
Hasegawa, A., et al. 2004. Proc. Natl. Acad. Sci. USA101, 6599.
Hasegawa, A., et al. 2004. Proc. Natl. Acad. Sci. USA101, 6599.
H₂N-Tyr-Cys*-Asp-Glu-His-Phe-Cys*-Tyr-CO₂H, Cyclic [disulfide bond between Cys-Cys]
Legal Information
Sold under license of U.S. Patent 7,288,519.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Thais F C Fraga-Silva et al.
iScience, 26(12), 108366-108366 (2023-12-04)
Airway epithelial cells (AEC) infected with SARS-CoV-2 may drive the dysfunction of macrophages during COVID-19. We hypothesized that the direct interaction of AEC with macrophages mediated by CD95/CD95L or indirect interaction mediated by IL-6 signaling are key steps for the
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 341291-25MG | 04055977215618 |